An impactful blend of benefits that helps you take control
…OF THE OS PFS ORR
DISEASE1
*Vs sunitinib.
…OF THE
TREATMENT EXPERIENCE1-3
Superior tolerability vs sunitinib1-3
An optimised, easily-adjustable CABOMETYX® dose with a predictable tolerability and a low rate of discontinuations due to TRAEs1-3
…OF THE
PATIENT EXPERIENCE1
The only 1L TKI+CPI combination to consistently demonstrate a superior QoL profile vs sunitinib1,4,5
… and give your patients a chance to live longer and
better*1
1. Bourlon MT, et al. Abstract 362. Presented at ASCO GU 2024. 2. Motzer RJ, et al. Lancet Oncol 2022;23(7):888-898 3. Motzer RJ, et al. Lancet Oncol 2022;23(7):888-898. (Supplemental appendix). 4. Motzer R, et al. Lancet Oncol 2022;23(6):768-780 5. Bedke J, et al. Eur Urol. 2022;82(4):427-439
All materials used in activities and interactions must be reviewed and approved in accordance with applicable procedural documents prior to their use.
CBZ-ALL-005141 | February 2024
CABOMETYX®
Take control of aRCC with the TKI+CPI of choice in 1L
The TKI of choice*1
CABOMETYX® + NIVOLUMAB
Approved and recommended across all IMDC risk groups†1-5
NIVOLUMAB
An established CPI in aRCC6,7
May 2018
2L monotherapy8
1L monotherapy9
Mar 2021
Jan 2019
Sep 2016 Apr 2016
1L combination10 (nivolumab + ipilimumab)
2L monotherapy11
CABOMETYX® + nivolumab has an absolute mOS gain of 10.5 months vs sunitinib – the longest of any TKI+CPI‡12-14
*ESMO-recommended as the preferred option in 1L advanced papillary RCC and among the recommended options in relevant aRCC settings. †Recommended by the ASCO, EAU, ESMO and NCCN guidelines. ‡As of January 2024 Click here to see references.
All materials used in activities and interactions must be reviewed and approved in accordance with applicable procedural documents prior to their use.
CBZ-ALL-005141 | February 2024